

Product datasheet for TL313600V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

CYP2A13 Human shRNA Lentiviral Particle (Locus ID 1553)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: CYP2A13 Human shRNA Lentiviral Particle (Locus ID 1553)

Locus ID: 1553

Synonyms: CPAD; CYP2A; CYPIIA13

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: CYP2A13 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 000766, NM 000766.1, NM 000766.2, NM 000766.3, NM 000766.4, BC148422, BC153000,

BM975825, NM 000766.5

UniProt ID: Q16696

Summary: This gene encodes a member of the cytochrome P450 superfamily of enzymes. The

cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. Although its endogenous substrate has not been determined,

it is known to metabolize 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a major

nitrosamine specific to tobacco. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. [provided by RefSeq, Jul

2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





CYP2A13 Human shRNA Lentiviral Particle (Locus ID 1553) - TL313600V

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).